February 20, 2020

Choosing Wisely: Capitalizing on Atopic Dermatitis Clinical Trial Data for Meaningful Selection of Topical Agents

Drs. Lawrence Eichenfield and Adam Friedman

We are finally getting what we asked for: Pharma is ponying up for head to head studies to provide us with meaningful data to help make better clinical decisions. However, these valuable projects are often with systemic agents, such as biologics, leaving topical treatments in the dust. To address this, Dr. Lawrence Eichenfield, Professor of Dermatology and Pediatrics, UCSD, and colleagues sought to make the most out of the data we do have on the litany of topical options for atopic dermatitis and provide efficacy and safety guidance (A for effort!). Tune in to hear what this dream team concocted about creams. Hear how an expert approaches new atopic dermatitis patients. Don’t miss out – this is all very topical.

JDD Article Referenced in this Podcast:
Topical Agents for the Treatment of Atopic Dermatitis
Lawrence F. Eichenfield MD, Thomas Luger MD, Kim Papp MD, Jonathan I. Silverberg MD PhD MPH, Debra Sierka PhD, Chuanbo Zang PhD, Anna M. Tallman PharmD, Michael A. Zielinski PharmD, William C. Ports DVM
J Drugs Dermatol. 2020;19(1):50-64. doi:10.36849/JDD.2020.4508

The CME for this activity expired February 2021.

Learning Objectives:
Upon completion of this enduring activity, participants should be able to:
discuss the efficacy and safety of different topicals indicated for topic dermatitis,
as well as unique approaches to managing this complex yet extremely common condition.

Lawrence Eichenfield has been a consultant, investigator, data safety monitoring board member, or speaker for AbbVie, Allergan, Anacor, Arcutis, Dermavant, Dermira, Eli Lilly, Galderma, LEO Pharma, Medimetriks, Novartis, Otsuka, Pfizer Inc., Regeneron, Sanofi-Genzyme, OrthoDerm/Valeant, and UCB.

Adam Friedman has been a consultant and speaker for Regeneron, Sanofi-Aventis, Ortho Dermatologics, and Pfizer.

Related Article